MNOV revenueQ2 2026$458.4K
- Quarter YoY
- +240.6%
- QoQ
- +145.2%
MNOV revenue was $458.4K in fiscal Q2 2026 (ended Jun 30, 2026), up 240.6% from a year earlier and up 145.2% from the prior quarter. For the full fiscal 2025 it was $409.7K.
Medicinova Inc (MNOV) financials
For the twelve months ended Jun 30, 2026, Medicinova Inc reported $920.5K of revenue and -$10.75M of net income.
- Revenue, TTM
- $920.5K
- Net income, TTM
- -$10.75M
- Net margin
- -1168.2%
- Free cash flow, TTM
- -$9.12M
- EPS, diluted, TTM
- -$0.21
- Cash
- $25.42M
- P/S
- 78.61
- Market cap
- $72.4M
FY2021FY2025
FY2016FY2025
FY2016FY2025
MNOV revenue and earnings growth
MNOV net incomeQ2 2026-$2.31M
MNOV net income was -$2.31M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$3.28M a year earlier. For the full fiscal 2025 it was -$12.00M, compared with -$11.05M in fiscal 2024.
MNOV EPSQ2 2026-$0.05
MNOV diluted EPS was -$0.05 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.07 a year earlier. For the full fiscal 2025 it was -$0.24, compared with -$0.23 in fiscal 2024.
MNOV free cash flowQ2 2026-$1.92M
MNOV free cash flow was -$1.92M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.31M a year earlier. For the full fiscal 2025 it was -$9.81M, compared with -$10.64M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $409.7K | - | $1.00M | - | $4.04M | - | - | - | - | - |
| Research and development | $6.70M | $6.80M | $5.30M | $8.70M | $8.10M | $7.10M | $5.70M | $5.30M | $3.90M | $3.10M |
| Selling, general and admin | $6.16M | $5.48M | $5.24M | $5.48M | $5.72M | $6.69M | $7.95M | $9.96M | $8.80M | $7.36M |
| Operating income | -$13.28M | -$12.68M | -$9.90M | -$14.63M | -$10.22M | -$14.18M | -$14.03M | -$15.59M | -$13.03M | -$10.88M |
| Interest expense | - | - | - | - | - | - | - | - | $298 | $454 |
| Pre-tax income | -$11.99M | -$11.04M | -$8.57M | -$14.07M | -$10.13M | -$13.86M | -$12.93M | -$14.67M | -$12.91M | -$10.86M |
| Income tax | $6.0K | $5.5K | $3.0K | $2.8K | $2.6K | -$1.6K | $12.7K | $5.3K | -$1.74M | $3.8K |
| Net income | -$12.00M | -$11.05M | -$8.57M | -$14.07M | -$10.13M | -$13.85M | -$12.94M | -$14.68M | -$11.16M | -$10.87M |
| EPS, basic | -$0.24 | -$0.23 | -$0.17 | -$0.29 | -$0.21 | -$0.31 | -$0.30 | -$0.36 | -$0.32 | -$0.33 |
| EPS, diluted | -$0.24 | -$0.23 | -$0.17 | -$0.29 | -$0.21 | -$0.31 | -$0.30 | -$0.36 | -$0.32 | -$0.33 |
| Diluted shares | 49.1M | 49.0M | 49.0M | 49.0M | 48.6M | 44.4M | 43.2M | 41.1M | 35.1M | 33.0M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $30.81M | $40.36M | $51.00M | $18.51M | $71.43M | $60.04M | $63.79M | $62.31M | $27.99M | $24.12M |
| Short-term investments | - | - | - | $39.98M | - | - | - | - | - | - |
| Receivables | $0 | $0 | - | - | $0 | - | - | - | - | - |
| Current assets | $30.99M | $41.07M | $51.17M | $58.99M | $72.01M | $60.72M | $64.30M | $62.76M | $28.33M | $24.70M |
| Goodwill | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M |
| Total assets | $45.60M | $55.88M | $66.27M | $74.15M | $87.41M | $75.42M | $79.21M | $77.22M | $43.42M | $39.81M |
| Current liabilities | $3.80M | $2.96M | $3.28M | $3.19M | $2.83M | $2.19M | $2.23M | $2.19M | $2.88M | $1.63M |
| Total liabilities | $4.02M | $3.37M | $3.89M | $3.91M | $3.73M | $4.09M | $4.31M | $4.12M | $4.78M | $5.28M |
| Shareholders' equity | $41.59M | $52.50M | $62.38M | $70.24M | $83.68M | $71.33M | $74.89M | $73.11M | $38.64M | $34.53M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.81M | -$10.64M | -$7.43M | -$12.91M | -$9.38M | -$10.83M | -$9.12M | -$9.11M | -$6.92M | -$6.55M |
| Capital expenditures | $2.9K | $895 | $21.3K | $5.0K | $28.7K | $36.5K | $11.3K | $10.2K | - | $84.5K |
| Free cash flow | -$9.81M | -$10.64M | -$7.45M | -$12.92M | -$9.41M | -$10.86M | -$9.14M | -$9.12M | - | -$6.63M |
| Investing cash flow | -$2.9K | -$697 | $39.91M | -$40.01M | -$28.7K | -$36.5K | -$11.3K | $626.3K | - | -$84.5K |
| Financing cash flow | $244.0K | $0 | - | $7.9K | $20.78M | $7.11M | $10.62M | $42.81M | $10.80M | $8.67M |
| Stock-based compensation | $829.1K | $1.19M | $710.7K | $642.5K | $1.72M | $3.18M | $4.11M | $6.33M | $4.47M | $3.97M |
| Depreciation and amortization | $20.1K | $21.1K | $20.3K | $17.7K | $26.1K | $21.3K | $23.9K | $25.9K | $28.1K | $14.1K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -3242.5% | - | -990.0% | - | -253.0% | - | - | - | - | - |
| Net margin | -2928.8% | - | -857.2% | - | -251.0% | - | - | - | - | - |
| Free cash flow margin | -2395.4% | - | -745.2% | - | -233.1% | - | - | - | - | - |
| Return on equity | -28.9% | -21.0% | -13.7% | -20.0% | -12.1% | -19.4% | -17.3% | -20.1% | -28.9% | -31.5% |
| Return on assets | -26.3% | -19.8% | -12.9% | -19.0% | -11.6% | -18.4% | -16.3% | -19.0% | -25.7% | -27.3% |
| Current ratio | 8.16 | 13.88 | 15.61 | 18.51 | 25.42 | 27.67 | 28.86 | 28.63 | 9.83 | 15.16 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $458.4K | $187.0K | $151.7K | $123.3K | $134.6K | $0 | - | - | - | - | $0 | $1.00M |
| Research and development | $900.0K | $1.20M | $1.40M | $1.50M | $2.00M | $1.70M | $1.80M | $1.80M | $1.50M | $1.70M | $1.60M | $700.0K |
| Selling, general and admin | $1.83M | $1.59M | $1.55M | $1.81M | $1.44M | $1.36M | $1.28M | $1.45M | $1.40M | $1.35M | $839.3K | $1.35M |
| Operating income | -$2.54M | -$2.84M | -$3.09M | -$3.38M | -$3.61M | -$3.20M | -$3.18M | -$3.31M | -$3.05M | -$3.14M | -$2.49M | -$1.15M |
| Net income | -$2.31M | -$2.59M | -$2.80M | -$3.05M | -$3.28M | -$2.86M | -$2.81M | -$2.85M | -$2.63M | -$2.75M | -$2.06M | -$723.1K |
| EPS, basic | -$0.05 | -$0.05 | -$0.05 | -$0.06 | -$0.07 | -$0.06 | -$0.06 | -$0.06 | -$0.05 | -$0.06 | -$0.04 | -$0.01 |
| EPS, diluted | -$0.05 | -$0.05 | -$0.05 | -$0.06 | -$0.07 | -$0.06 | -$0.06 | -$0.06 | -$0.05 | -$0.06 | -$0.04 | -$0.01 |
| Diluted shares | 49.2M | 49.2M | - | 49.0M | 49.0M | 49.0M | - | 49.0M | 49.0M | 49.0M | - | 49.0M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $25.42M | $27.33M | $30.81M | $32.56M | $34.26M | $36.57M | $40.36M | $42.28M | $44.34M | $47.14M | $51.00M | $51.51M |
| Receivables | $0 | $245.1K | $0 | $0 | $134.6K | - | $0 | - | - | - | - | $1.00M |
| Current assets | $25.92M | $28.15M | $30.99M | $32.92M | $35.12M | $37.68M | $41.07M | $43.27M | $45.51M | $47.86M | $51.17M | $53.00M |
| Goodwill | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M |
| Total assets | $40.43M | $42.70M | $45.60M | $47.58M | $49.82M | $52.43M | $55.88M | $58.12M | $60.40M | $62.89M | $66.27M | $68.14M |
| Current liabilities | $2.96M | $3.10M | $3.80M | $3.34M | $2.65M | $2.13M | $2.96M | $2.60M | $2.49M | $2.51M | $3.28M | $2.80M |
| Total liabilities | $3.16M | $3.30M | $4.02M | $3.61M | $2.97M | $2.50M | $3.37M | $3.05M | $3.00M | $3.06M | $3.89M | $3.47M |
| Shareholders' equity | $37.27M | $39.41M | $41.59M | $43.96M | $46.86M | $49.93M | $52.50M | $55.07M | $57.41M | $59.83M | $62.38M | $64.67M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.92M | -$3.47M | -$2.02M | -$1.70M | -$2.31M | -$3.78M | -$1.93M | -$2.03M | -$2.81M | -$3.87M | -$499.1K | -$1.37M |
| Capital expenditures | $0 | $10.8K | $0 | $2.9K | $0 | $0 | -$2 | $6 | - | - | -$22 | $2.7K |
| Free cash flow | -$1.92M | -$3.48M | -$2.02M | -$1.71M | -$2.31M | -$3.78M | -$1.93M | -$2.03M | - | - | -$499.1K | -$1.37M |
| Investing cash flow | $0 | -$10.8K | $0 | -$2.9K | $0 | $0 | $1 | $193 | - | - | $22 | -$2.7K |
| Stock-based compensation | $176.8K | $407.8K | $180.6K | $157.7K | $204.9K | $285.9K | $264.0K | $504.9K | $207.5K | $215.4K | -$237.4K | $219.1K |
| Depreciation and amortization | $5.0K | $4.3K | $4.6K | $5.3K | $5.1K | $5.2K | $5.2K | $5.2K | $5.4K | $5.3K | $5.5K | $5.7K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 240.6% | - | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -554.3% | -1516.6% | -2038.0% | -2741.7% | -2679.9% | - | - | - | - | - | - | -114.7% |
| Net margin | -504.8% | -1383.1% | -1846.8% | -2473.6% | -2437.7% | - | - | - | - | - | - | -72.3% |
| Free cash flow margin | -418.8% | -1861.7% | -1329.1% | -1383.5% | -1713.5% | - | - | - | - | - | - | -137.4% |
| Current ratio | 8.75 | 9.09 | 8.16 | 9.86 | 13.26 | 17.66 | 13.88 | 16.66 | 18.24 | 19.07 | 15.61 | 18.92 |
Source: XBRL data Medicinova Inc files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
MNOV peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MNOV | $920.5K | - | -$10.75M | -1168.2% | $72.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
MNOV FAQ
7 questionsWhat is MNOV revenue?
Medicinova Inc (MNOV) reported $920.5K of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $409.7K.Is MNOV profitable?
No. Medicinova Inc reported a net loss of $10.75M for the twelve months ended Jun 30, 2026.How much cash and debt does MNOV have?
Medicinova Inc reported $25.42M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is MNOV free cash flow?
Medicinova Inc generated -$9.12M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$9.11M less capital expenditures.What is MNOV earnings per share?
Diluted earnings per share were -$0.21 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did MNOV last report financial results?
The latest statements here come from Medicinova Inc's 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this MNOV financial data come from?
Quantisnow builds these statements from the structured XBRL data Medicinova Inc files with the SEC. It is provided for information only and is not investment advice.